Legal DevelopmentsThe Delaware Supreme Court's decision to hear GSK’s appeal suggests a reasonable chance of overturning the previous decision, which could lead to a significantly reduced liability threat.
Market ExpansionThe broader European rollout of Shingrix is progressing well, with France identified as the next major opportunity for expansion.
Product LaunchesDepemokimab, an asthma treatment, is anticipated to be well-received as the first Q6M regimen, reducing asthmatic exacerbations significantly in trials.